Biodesix Announces Agreement with Bruker Daltonics
News Apr 24, 2013
VeriStrat is a novel, multivariate serum protein test that helps oncologists personalize therapy for patients with lung cancer. The new collaboration advances the companies’ existing relationship concerning use of Bruker’s state of the art MALDI-TOF instruments with VeriStrat and Biodesix’ other clinical diagnostics in development. The agreement provides avenues for valuable hardware and software/applications support as well as access to the latest in instrument designs and improvements.
MALDI-TOF mass spectrometry is a powerful analytical platform that can provide detailed and discriminating information about complex biological samples, but with relatively simple sample preparation and high throughput. The combination of Biodesix’ platform technology, including Biodesix’ sophisticated and proprietary data analysis algorithms, and Bruker instruments, valued for their outstanding performance, reliability, and innovative designs forms the basis for a robust clinical diagnostics platform.
“We are pleased to solidify our relationship with one of our key partners with this new agreement,” stated Gary Pestano, PhD, Head of Product Development and Lab Operations at Biodesix. “The support we receive from Bruker will substantially benefit both the delivery and development of our diagnostic tests.”
Gary Kruppa, Vice President for Business Development at Bruker Daltonics commented, “We have been impressed with Biodesix’ capabilities for development of MALDI-TOF mass spectrometry based diagnostic assays. We are delighted to work even more closely with Biodesix to support their goals, which of course we also expect will increase the market for Bruker’s innovative MALDI-TOF mass spectrometers in diagnostics.”